Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Maria Mercedes Santoro
Observed name:
Santoro, Maria Mercedes
Institution:
University of Rome Tor Vergata
Observed institution:
University of Rome Tor Vergata
ORCID:
0000-0002-6228-1114
Observed ORCID:
0000-0002-6228-1114
OpenAlex ID:
A5106024117
Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions
2025
·
Anna Maria Geretti
, Marta Boffito
, et al.
·
Open Forum Infectious Diseases
·
17
PDF
Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO Registry
2024
·
Daniele Armenia
, Vincenzo Spagnuolo
, et al.
·
Journal of Antimicrobial Chemotherapy
·
7
Next-generation sequencing and drug resistance mutations of HIV-1 subtypes in people living with HIV in Sicily, Italy, 2021–2023
2024
·
Luca Pipitò
, Marcello Trizzino
, et al.
·
Journal of Global Antimicrobial Resistance
·
6
Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen
2016
·
Andrea De Luca
, Philippe Flandre
, et al.
·
Journal of Antimicrobial Chemotherapy
·
6
PDF
Durability of lenacapavir in viremic heavily treatment-experienced people with HIV: real-world data from the PRESTIGIO Registry
2025
·
Tommaso Clemente
, Golnaz Torkjazi
, et al.
·
Journal of Antimicrobial Chemotherapy
·
4
Risk of clinical events in virologically suppressed people with HIV switching to a two-drug regimen vs. remaining on a three-drug regimen: a target trial emulation
2025
·
Cristina Mussini
, Andrea Giacomelli
, et al.
·
EClinicalMedicine
·
4
PDF
Confirmed virological failure following enhanced adherence counseling among virally unsuppressed children and adolescents on dolutegravir-based versus other regimens: Evidence from a cohort analysis in Cameroon
2025
·
Yagai Bouba
, Aude Christelle Ka’e
, et al.
·
Medicine
·
4
Low burden of clinically relevant anaemia and thrombocytopenia among adolescents living with HIV receiving tenofovir/lamivudine plus dolutegravir: the CIPHER-ADOLA study in Cameroon
2025
·
Nadine Nguendjoung Fainguem
, Yagai Bouba
, et al.
·
AIDS Research and Therapy
·
2
Teropavimab and zinlirvimab sensitivity in people living with multidrug-resistant HIV-1: data from the PRESTIGIO Registry
2025
·
Vincenzo Spagnuolo
, Laura Galli
, et al.
·
Microbiology Spectrum
·
2
Evaluation of HIV-1 transmitted drug-resistance among subtypes circulating from 2022 to 2024 in Italy: a refined analysis through next-generation sequencing
2026
·
Daniele Armenia
, Claudia Alteri
, et al.
·
Journal of Antimicrobial Chemotherapy
·
1
Development of a Next‐Generation Sequencing Protocol for Assessing Lenacapavir Resistance in HIV‐1 Capsid
2025
·
Omar El Khalili
, Collins Ambe Chenwi
, et al.
·
Journal of Medical Virology
·
1
PDF
PRESTIGIO RING "a 59-year-old man with multidrug resistant HIV-1 infection failing a regimen including dolutegravir, rilpivirine, atazanavir/cobicistat: successful treatment tailoring based on genotypic and phenotypic resistance tests".
2024
·
Francesca Panza
, Francesco Saladini
, et al.
·
PubMed
·
1
PDF
Virological outcomes, resistance profile and viral evolution of lenacapavir-based regimens in heavily treatment-experienced people: data from the PRESTIGIO Registry
2026
·
Maria Mercedes Santoro
, Daniele Spalletta
, et al.
·
Journal of Antimicrobial Chemotherapy
PDF
Obesity at antiretroviral therapy initiation and long-term risk of cardiovascular disease, cancer, or death in people with HIV in Italy: a prospective cohort study
2026
·
Cristina Mussini
, Andrea Giacomelli
, et al.
·
EClinicalMedicine
Impact of DNA-stored mutations on virological response in virologically suppressed PWH in the switch to modern regimens
2025
·
Francesca Lombardi
, Elio Gentilini Cacciola
, et al.
·
International Journal of Antimicrobial Agents
All-Cause Mortality in People With Four-Class Drug-Resistant HIV: A Matched Cohort Analysis With Data From the PRESTIGIO Registry
2025
·
Andrea Giacomelli
, Nicolò Capra
, et al.
·
Clinical Infectious Diseases
PDF
Persistence of CXCR4-tropic virus in people living with four-class drug-resistant HIV and its clinical impact in the modern antiretroviral era
2025
·
Rebecka Papaioannu Borjesson
, Sara Diotallevi
, et al.
·
Journal of Antimicrobial Chemotherapy
PDF
Time fixes everything, but not always: 10 years of persistent PI mutations in the absence of pharmacological pressure—a case report
2025
·
Layla Pagnucco
, Antonella Castagna
, et al.
·
Journal of Antimicrobial Chemotherapy
HIV susceptibility to second-generation integrase strand transfer inhibitors among people with multidrug resistance: a systematic review and meta-analysis protocol
2025
·
Vincent Kamaël Mekel
, Ezechiel Ngoufack Jagni Semengue
, et al.
·
Therapeutic Advances in Infectious Disease
Show more works
View as search
Works count:
21
Citation count:
55
H-index:
4
I10-index:
1
Year
Topic
Type